Wockhardt jump 13% as US FDA accepts NDA for Zaynich antibiotic in key milestone for Indian pharma
Shares of Indian pharmaceutical major Wockhardt rallied more than 13% on Monday after it announced a milestone development in its...
Shares of Indian pharmaceutical major Wockhardt rallied more than 13% on Monday after it announced a milestone development in its...
Airbus share price moved sideways as investors assessed the impact of last week’s recall of its most important jet. AIR...
The post South Korea cyber crisis deepens as Coupang data leak exposes national vulnerabilities appeared first on Invezz
Tesla trades just shy of a $1.3 trillion market cap.And with shareholders now greenlighting an eye-popping pay package for Elon...
Hopes for a potential peace plan in Ukraine have sent shockwaves through the energy market this week, causing the gasoil...
Gold is beating Bitcoin by a wide margin, and the explanation lies not just in price charts but in who’s...
As the AI boom continues, talk of a potential OpenAI IPO is accelerating in the United States. This talk accelerated...
The post Winners vs. losers in a bruised November: can the S&P 500 recover in December? appeared first on Invezz
Goldman Sachs analyst Jacqueline Du sees explosive growth in humanoid robot orders in 2026.And given that Tesla Inc.’s (NASDAQ: TSLA)...
SMX stock exploded more than 200% on Friday, after unveiling a breakthrough molecular verification system designed for aerospace metals. The...
Disclaimer: EarningsMastery.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.